HOME >> MEDICINE >> NEWS
Clinical study results using Aldagen's product to isolate cord blood stem cells presented at ASH

Durham, NC -- December 11, 2006 Aldagen, Inc. today announced the presentation of data from a clinical trial using its ALDESORT product to isolate stem cells from cord blood. The trial is being conducted by Joanne Kurtzberg, MD, the Duke University physician who pioneered the use of umbilical cord blood as a treatment for fatal childhood cancers and genetic diseases in 1993. Dr. Kurtzberg presented positive interim results of the study at the 48th Annual Meeting of the American Society of Hematology in Orlando, Florida.

About the Study
ALDESORT enriches a unique population of stem and progenitor cells from cord blood that contribute to neutrophil and platelet engraftment and to immune reconstitution following transplantation. The primary goal of the clinical study is to determine if transplanting these enriched cells is safe. The study will also indicate if transplanting these cell populations could result in accelerated engraftment and lead to more favorable clinical outcomes compared to a historical control group from the Cord Blood Transplantation Trial (COBLT) study, a multicenter Phase II study sponsored by the National Heart, Lung and Blood Institute. At the time of the interim analysis, eleven pediatric patients with cancer or genetic diseases were transplanted with unrelated donor umbilical cord blood and a supplement of cord cells isolated using ALDESORT. Overall survival at 180 days was 90.9%, compared to an overall survival at 180 days of 57% in COBLT study. The cumulative incidence of neutrophil engraftment by day 42 was 90.9% (p=0.001) and platelet engraftment by day 100 was 79.5% (p=0.003).

The findings of this study once again show the promise of transplanting stem cells from umbilical cord blood to treat children with resistant cancers and genetic diseases, said Dr. Kurtzberg. The infusion of cells enriched with ALDESORT has had no adverse effects and appears to improve the speed and efficacy of cord bloo
'"/>

Contact: Michelle Linn
linnmich@comcast.net
508-419-1555
Linnden Communications
11-Dec-2006


Page: 1 2

Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
6. Clinical guidelines for blood conservation during cardiac procedures developed
7. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
8. Clinical trial coordinators need more financial conflict-of-interest training
9. Clinical studies evaluate potential treatments for mouth ulcers
10. NIH names Clinical Trial Units for the Microbicide Trials Network
11. Clinical Trials Units selected for newly restructured HIV/AIDS research networks

Post Your Comments:
(Date:7/28/2015)... ... ... Morristown Medical Center, part of Atlantic Health System, today announced it was ... the nation, to implant the newly approved CoreValve® Evolut® R System from Medtronic. The ... condition. , The CoreValve® Evolut® R System was approved by the U.S. Food and ...
(Date:7/28/2015)... Francisco, California (PRWEB) , ... July 28, 2015 , ... ... the results from a recent survey (1) examining consumers’ perspectives on digital ... June 17-24, 2015, covered topics such as innovations in digital health, level of trust ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Aziz Ahmad ... The talk took place from noon to 1 p.m. Tuesday, June 23, at the ... Fla. , Dr. Ahmad is board-certified in colorectal surgery and has more than ...
(Date:7/28/2015)... ... ... to Kxan on June 24th a previously FDA approved blood pressure medication ... isradipine has garnered national attention and is making drug and alcohol rehabilitation medical physicians ... The study was conducted by the University of Texas. Human trials may be set ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... Kinetic Data announced that Schneider Electric has completed its upgrade and expansion ... a global organization with more than 170,000 employees in 134 countries supplying a ...
Breaking Medicine News(10 mins):Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 2Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 3Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 4Health News:Consumers Concerned About Privacy of Personal Health Data on Wearables and Mobile Apps, According to New Healthline Survey 5Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4
(Date:7/28/2015)... 2015  For many medical institutions and universities, commercializing ... inventors can be a constant challenge. Taking an idea ... are rare. A new company in ... Medical Device Investments (MDI) was created to commercialize ... physicians. MDI develops, manufactures and markets the products, with ...
(Date:7/28/2015)... , July 28, 2015   CSL ... for review a Marketing Authorization Application (MAA) for ... coagulation factor IX with recombinant albumin (rIX-FP) for ... people with Hemophilia B. Upon Swissmedic approval, rIX-FP ... treatment option with dosing intervals up to 14 ...
(Date:7/28/2015)... , July 28, 2015 VirtualScopics, Inc. (NASDAQ: ... imaging solutions, today announced that it will report its ... ET market close on Tuesday, August 11, 2015.  ... and Jim Groff , chief financial officer, will ... company,s financial results and provide a business update at ...
Breaking Medicine Technology:Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3
Cached News: